Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection
Authors:
- Leslie A LenertLLLeslie A Lenert
- Martin FeddersenMFMartin Feddersen
- Ann SturleyASAnn Sturley
- Daniel LeeDLDaniel Lee
- 1 August 2002
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 113 (3) , 229-232
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- The reliability and internal consistency of an Internet-capable computer program for measuring utilitiesQuality of Life Research, 2000
- Hit HIV-1 hard, but only when necessaryThe Lancet, 2000
- Effects on Preferences of Violations of Procedural InvarianceMedical Decision Making, 1999
- Variations in the Care of HIV-Infected Adults in the United StatesJAMA, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Lipodystrophy and altered body shape in HIV: A protease inhibitor side effect? What do you tell your patient? (CEU)The Case Manager, 1999
- Lipodystrophy Associated with an HIV-Protease InhibitorNew England Journal of Medicine, 1998
- The Effect of Search Procedures on Utility ElicitationsMedical Decision Making, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996